| Li, Ning |
NCT04351867: A Clinical Trial of Two Adjuvant Chemotherapy Regimens for Postoperative Gastric Cancer |
|
|
| Not yet recruiting | 3 | 196 | RoW | docetaxel plus oxaliplatin and capecitabine, Three medicine combined, oxaliplatin plus capecitabine, Two medicine combined | LiNing | Stomach Neoplasms | 06/24 | 06/24 | | |
NCT06658353: Phase III Clinical Study of VC004 in Patients With Localized Advanced/ Metastatic Solid Tumors |
|
|
| Not yet recruiting | 3 | 54 | RoW | VC004 Capsules | Jiangsu vcare pharmaceutical technology co., LTD | Locally Advanced Solid Tumor | 12/26 | 12/26 | | |
SUNRAY-01, NCT06119581: A Study of First-Line Olomorasib (LY3537982) and Pembrolizumab With or Without Chemotherapy in Patients With Advanced KRAS G12C-Mutant Non-small Cell Lung Cancer |
|
|
| Recruiting | 3 | 1016 | Europe, Canada, Japan, US, RoW | LY3537982, Olomorasib, Pembrolizumab, Placebo, Cisplatin, Carboplatin, Pemetrexed | Eli Lilly and Company, Loxo Oncology, Inc. | Carcinoma, Non-Small-Cell Lung, Neoplasm Metastasis | 10/26 | 10/29 | | |
NCT05019794: Infigratinib in Subjects With GC or GEJ With FGFR2 Amplification or Other Solid Tumors With Other FGFR Alterations |
|
|
| Recruiting | 2a | 80 | RoW | Infigratinib, BGJ398 | LianBio LLC | Gastric Cancer, Gastroesophageal Junction Adenocarcinoma, Solid Tumor | 12/22 | 12/23 | | |
|
NCT03950271: SHR-1210 Combined With Trastuzumab , Oxaliplatin and Capecitabine for Neoadjuvant Therapy of Gastric Adenocarcinoma/Gastroesophageal Junction Adenocarcinoma |
|
|
| Active, not recruiting | 2 | 25 | RoW | SHR-1210 Combined With Trastuzumab , Oxaliplatin and Capecitabine | Henan Cancer Hospital | Gastric Cancer | 01/24 | 12/26 | | |
NCT04341857: PD-1 Monoclonal Antibody Combined With FLOT Regimen for Neoadjuvant Therapy of Gastric Adenocarcinoma |
|
|
| Recruiting | 2 | 25 | RoW | PD-1 Monoclonal Antibody(Sintilimab) | Henan Cancer Hospital | Gastric and Esophagogastric Junction Adenocarcinoma | 05/22 | 07/22 | | |
NCT04423185: PLATFORM Study of Precision Medicine for Rare Tumors |
|
|
| Not yet recruiting | 2 | 770 | NA | Almonertinib 110 MG, HS-10296, AMEILE, Dacomitinib 45 MG, Vizimpro, Alectinib 150 MG, Alecensa, Crizotinib 250 MG, Xalkori, Pyrotinib 160/80 MG, SHR-1258, Imatinib 400 MG, Gleevec, Niraparib 200/300 MG, Niraparix, Palbociclib 125mg, Ibrance, Vemurafenib 240 MG, Zelboraf, Sintilimab 100MG, Tyvyt, Atezolizumab 1680 MG, TECENTRIQ | Cancer Institute and Hospital, Chinese Academy of Medical Sciences | Rare Tumor | 07/22 | 07/23 | | |
NCT04062058: A Phase II Study of Total Neoadjuvant Therapy for Locally Advanced Gastric Cancer |
|
|
| Recruiting | 2 | 82 | RoW | SIB-IMRT, S-1, SOX, Surgery | Jing Jin, M.D., Beijing Hope Run | Gastric Cancer, Neoadjuvant Therapy | 09/22 | 09/23 | | |
NeoTOP, NCT06618014: Neoadjuvant Toripalimab Plus Liposomal Paclitaxel and Carboplatin in Patients With Localized TNBC |
|
|
| Recruiting | 2 | 46 | RoW | Toripalimab, Liposomal paclitaxel, Carboplatin | Sun Yat-sen University | Breast Cancer, Triple Negative Breast Cancer | 03/25 | 03/28 | | |
NCT04614740: The Phase I/Phase II Clinical Study of VC004 in Patients With Localized Advanced/Metastatic Solid Tumors |
|
|
| Recruiting | 2 | 115 | RoW | VC004 | Jiangsu vcare pharmaceutical technology co., LTD | Locally Advanced Solid Tumor, Metastatic Solid Tumor | 01/24 | 06/24 | | |
NCT06322095: A Study of GH21 Combined With Previous Target Therapy or Immunotherapy in Patients With Advanced Solid Tumors |
|
|
| Recruiting | 2 | 72 | RoW | PD-1, MET inhibitor, ALK inhibitor, BRAF Inhibito, EGFR Monoclonal antibody, GH21, MEK Inhibitor | Suzhou Genhouse Bio Co., Ltd. | Patients With Advanced Solid Tumor, Advanced Solid Tumor With Oncogenic Driver Mutations | 09/25 | 12/25 | | |
NCT06490068: Study of LTC004 Combine With Toripalimab in Patient With Solid Tumors Resistant to Immunotherapy |
|
|
| Recruiting | 2 | 10 | RoW | LTC004+Toripalimab, LTC004 combine with Toripalimab | Cancer Institute and Hospital, Chinese Academy of Medical Sciences | Advanced Solid Tumor | 03/26 | 03/26 | | |
NCT05221658: A Phase II Clinical Study to Evaluate the Efficacy and Safety of HLX07 Combination Therapy or Monotherapy in Patients With Advanced ESCC |
|
|
| Recruiting | 2 | 60 | RoW | HLX07+HLX10+ Cisplatin+5-FU, HLX07 | Shanghai Henlius Biotech | ESCC or Esophageal Adenosquamous Carcinoma | 06/24 | 08/25 | | |
| Not yet recruiting | 2 | 15 | RoW | ES014, ES014 for Injection | Cancer Institute and Hospital, Chinese Academy of Medical Sciences, Elpiscience (Suzhou) Biopharma, Ltd. | Advanced Solid Tumor | 06/26 | 09/26 | | |
| Not yet recruiting | 2 | 42 | RoW | Neratinib tablets, Epilepsy | Convalife (Shanghai) Co., Ltd. | NSCLC | 12/24 | 12/25 | | |
NCT04348643: Safety and Efficacy of CEA-Targeted CAR-T Therapy for Relapsed/Refractory CEA+ Cancer |
|
|
| Recruiting | 1/2 | 40 | RoW | CEA CAR-T cells | Chongqing Precision Biotech Co., Ltd | Solid Tumor, Lung Cancer, Colorectal Cancer, Liver Cancer, Pancreatic Cancer, Gastric Cancer, Breast Cancer | 12/23 | 04/24 | | |
TranStar102, NCT04495296: A Trial to Evaluate Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of TST001 in Advanced or Metastatic Solid Tumors |
|
|
| Recruiting | 1/2 | 320 | RoW | TST001, Oxaliplatin, Capecitabine, Paclitaxel, Gemcitabine, Cisplatin, Nivolumab | Suzhou Transcenta Therapeutics Co., Ltd., Bristol-Myers Squibb | Advanced Cancer | 02/25 | 05/25 | | |
NCT05260385: To Evaluate KC1036 in the Patients with Advanced Digestive System Tumors |
|
|
| Recruiting | 1/2 | 133 | RoW | KC1036 | Beijing Konruns Pharmaceutical Co., Ltd. | Digestive System Tumors | 10/25 | 12/25 | | |
| Recruiting | 1/2 | 134 | US, RoW | PRO1160 | ProfoundBio US Co. | Renal Cell Carcinoma, Nasopharyngeal Carcinoma, Non Hodgkin Lymphoma | 11/26 | 03/27 | | |
NCT06612632: Immunotherapy Rechallenge in Patients with Solid Tumors in Clinical Trials |
|
|
| Recruiting | 1/2 | 100 | RoW | research drug in combination with Toripalimab, Toripalimab | Cancer Institute and Hospital, Chinese Academy of Medical Sciences | Cancer | 06/26 | 06/28 | | |
CT041-ST-01, NCT04581473: Study to Evaluate the Efficacy, Safety and Pharmacokinetics of CT041 Autologous CAR T-cell Injection |
|
|
| Recruiting | 1/2 | 192 | RoW | CT041 autologous CAR T-cell injection, CAR T-cell injection, Physician's Choice（Paclitaxel or Irinotecan or Apatinib or Anti-PD-1 antibody）, Best support care(BSC) | CARsgen Therapeutics Co., Ltd., Peking University Cancer Hospital & Institute, Fudan University | Gastric Adenocarcinoma, Pancreatic Cancer, Gastroesophageal Junction Adenocarcinoma | 06/24 | 06/38 | | |
NCT05538195: Safety and Efficacy of CEA-targeted CAR-T for CEA-positive Advanced Malignant Solid Tumors |
|
|
| Recruiting | 1/2 | 60 | RoW | CEA-targeted CAR-T cells | Chongqing Precision Biotech Co., Ltd | Gastric Cancer, Colon Cancer, Rectal Cancer, Esophageal Cancer, Pancreatic Cancer | 12/24 | 06/25 | | |
| Recruiting | 1/2 | 354 | US, RoW | PRO1184, PRO1184 intravenous infusion of PRO1184 | Genmab | Platinum-Resistant Ovarian Cancer, Platinum Sensitive Ovarian Cancer (PSOC), High Grade Epithelial Ovarian Cancer, High Grade Serous Ovarian Cancer, Primary Peritoneal Carcinoma, Fallopian Tube Cancer, Endometrial Cancer, Non-small Cell Lung Cancer, Epidermal Growth Factor Receptor (EGFR)-Mutated Non-Small Cell Lung Cancer (NSCLC), Mesothelioma, Breast Adenocarcinoma, Triple Negative Breast Cancer, Hormone Receptor-positive/Her2 Negative Breast Cancer | 10/25 | 04/26 | | |
NCT06088004: Phase Ⅰ/Ⅱ Clinical Study to Evaluate ABO2011 in Advanced Solid Tumors |
|
|
| Recruiting | 1/2 | 218 | RoW | ABO2011 Injection, ABO2011, ABOD2011, Toripalimab | Suzhou Abogen Biosciences Co., Ltd., Abogen Biosciences (Shanghai) Co., Ltd | Solid Tumor, Adult | 12/26 | 12/27 | | |
NCT04615312: A Trail of CDK4 / 6 Inhibitor and MEK Inhibitor in the Treatment of Metastatic Digestive System Tumors |
|
|
| Recruiting | 1 | 50 | RoW | a CDK4 / 6 inhibitor and a MEK inhibitor | Henan Cancer Hospital | Digestive System Tumors | 08/21 | 08/22 | | |
NCT04326296: The Safety and Tolerability of PD-L1 Monoclonal Antibody Plus Lenalidomide in The Treatment of Colorectal Cancer |
|
|
| Not yet recruiting | 1 | 33 | RoW | PD-L1 Monoclonal Antibody Combined With Lenalidomide | LiNing | Colorectal Neoplasms | 09/22 | 03/23 | | |
NCT05881525: NY-ESO-1 TCR-T Cells for NY-ESO-1 Positive Subjects With Advanced Solid Tumors |
|
|
| Recruiting | 1 | 18 | RoW | TC-N201 cells, IL-2, Fludarabine, Cyclophosphamide, Nab-paclitaxel | TCRCure Biopharma Ltd., Cancer Institute and Hospital, Chinese Academy of Medical Sciences | Advanced Solid Tumors | 10/24 | 03/25 | | |
NCT06205082: A Phase I Clinical Trial to Evaluate LIT-00814 Tablets in Patients With Advanced Solid Tumor |
|
|
| Enrolling by invitation | 1 | 81 | RoW | LIT-00814 | LittDD Medicines Ltd | Advanced Solid Tumor | 10/25 | 06/26 | | |
KSX01-R08-102, NCT06150365: Single Arm Clinical Study on the Safety and Efficacy of Personalized KSX01-TCRT in Patients With Advanced Solid Tumors |
|
|
| Recruiting | 1 | 12 | RoW | KSX01-TCRT cell therapy | Cancer Institute and Hospital, Chinese Academy of Medical Sciences | Refractory Solid Tumors, Relapsed Solid Tumors | 12/26 | 12/28 | | |
NCT05152212: Study of LVGN7409 (CD40 Agonist Antibody) in Locally Advanced, Metastatic or Recurrent/Refractory Malignancy |
|
|
| Completed | 1 | 33 | RoW | LVGN7409 | Lyvgen Biopharma Holdings Limited | Cancer | 12/23 | 12/23 | | |
NCT06342336: HS-IT101 Injection in the Treatment of Advanced Solid Tumors |
|
|
| Recruiting | 1 | 44 | RoW | HS-IT101 Injection, HS-IT101 | Qingdao Sino-Cell Biomedicine Co., Ltd., Cancer Institute and Hospital, Chinese Academy of Medical Sciences, The First Hospital of Jilin University, West China Hospital | Solid Tumor | 03/26 | 03/28 | | |
| Recruiting | 1 | 60 | RoW | BT02 monoclonal antibody injection | Cancer Institute and Hospital, Chinese Academy of Medical Sciences | Advanced Solid Tumor | 12/24 | 12/24 | | |
NCT05183243: GH21 Capsules for Advanced Solid Tumors: A Study on Safety and Early Results |
|
|
| Recruiting | 1 | 68 | RoW | GH21 Capsule | Suzhou Genhouse Bio Co., Ltd. | Advanced Solid Tumor, Non-Small Cell Lung Cancer, Pancreatic Cancer, Colorectal Cancer, Head and Neck Neoplasm | 12/24 | 02/25 | | |
NCT06328673: A Study of DM919 Alone and in Combination With Pembrolizumab in Advanced Solid Tumors |
|
|
| Recruiting | 1 | 160 | US, RoW | DM919, Pembrolizumab, Keytruda | D2M Biotherapeutics Inc. | Advanced Solid Tumor | 12/25 | 03/26 | | |
NCT06346041: Safety and Efficacy of Intravenous IDOV-SAFETM in Patients With Advanced Solid Tumors |
|
|
| Recruiting | 1 | 19 | RoW | Oncolytic Virus injection(IDOV-SAFETM) | Cancer Institute and Hospital, Chinese Academy of Medical Sciences | Neoplasms | 12/24 | 04/26 | | |
| Recruiting | 1 | 112 | RoW | TQB3006 tablets | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | Advanced Malignant Neoplasm | 03/25 | 08/26 | | |
| Terminated | 1 | 3 | RoW | TQB2928 injection, Penpulimab | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | Advanced Malignant Neoplasm | 07/24 | 07/24 | | |
NCT06410131: Study in Patients With Advanced Solid Tumors to Evaluate the Safety of FTL008.16 |
|
|
| Not yet recruiting | 1 | 68 | RoW | FTL008.16 | Sound Biopharmaceuticals Ltd. | Solid Tumors | 01/26 | 05/27 | | |
NCT05886868: Phase I Study of BL0020, a Novel Anti-tumor Drug, in Adult Subjects With Advanced Solid Tumors |
|
|
| Recruiting | 1 | 66 | RoW | BL0020 | Shanghai Best-Link Bioscience, LLC | Advanced Solid Tumor | 07/24 | 02/25 | | |
| Not yet recruiting | 1 | 30 | NA | JYB1907, TGF-β inhibitor | Jemincare | Solid Tumor | 09/24 | 10/24 | | |
NCT06001684: Phase 1 Study of IBR854 in Locally Advanced Or Metastatic Solid Tumors |
|
|
| Recruiting | 1 | 18 | RoW | IBR854 Cell Injection | Imbioray (Hangzhou) Biomedicine Co., Ltd. | Solid Tumors | 09/24 | 12/24 | | |
NCT06610227: A Study of the RNA Tumor Vaccine Targeting MICA/B in Patients with Advanced Solid Tumors |
|
|
| Not yet recruiting | 1 | 18 | NA | SapRNA™-MICA/B Tumor Vaccine | NING LI | Advanced Solid Tumors | 10/25 | 10/26 | | |
| Recruiting | 1 | 122 | RoW | SG1827 | Hangzhou Sumgen Biotech Co., Ltd. | Advanced Solid Tumors | 12/24 | 03/25 | | |
| Recruiting | 1 | 100 | RoW | HQP1351 | Ascentage Pharma Group Inc., HealthQuest Pharma Inc. | Gastrointestinal Stromal Tumor (GIST), Solid Tumor, Adult | 12/24 | 12/26 | | |
NCT05392699: ABOD2011 in Patients With Advanced Solid Tumors Progressed After Standard Systemic Therapy |
|
|
| Recruiting | 1 | 60 | RoW | human single chain IL-12 mRNA-single dose, human single chain IL-12 mRNA-multiple dose | Cancer Institute and Hospital, Chinese Academy of Medical Sciences | Patients With Advanced Solid Tumors | 03/25 | 01/27 | | |
NCT05244551: A Study to Assess Safety, Tolerability, and Pharmacokinetics of ABSK061 in Patients With Advanced Solid Tumors |
|
|
| Recruiting | 1 | 85 | US, RoW | ABSK061 | Abbisko Therapeutics Co, Ltd | Solid Tumor | 04/25 | 04/25 | | |
| Recruiting | 1 | 71 | RoW | TQB2103 for injection | Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd. | Advanced Malignant Neoplasm | 05/25 | 05/25 | | |
NCT06050980: Phase I Study of HSK40118 in NSCLC Patients With EGFR Mutation |
|
|
| Recruiting | 1 | 220 | RoW | HSK40118 | Haisco Pharmaceutical Group Co., Ltd. | NSCLC | 08/25 | 06/27 | | |
NCT05946226: A Phase I Trial to Evaluate the Safety of IMC002 in Advanced Digestive System Tumors |
|
|
| Recruiting | 1 | 18 | RoW | IMC002 injection, Autologous Claudin 18.2 specific CAR-T cell injection | Suzhou Immunofoco Biotechnology Co., Ltd | Advanced Digestive System Tumor | 12/25 | 12/25 | | |
NCT06314542: Quantitative Evaluation of the Impact of Relaxing Eligibility Criteria for Lung Cancer Based on Real-world Data |
|
|
| Recruiting | N/A | 50000 | RoW | relaxing eligibility criteria | Cancer Institute and Hospital, Chinese Academy of Medical Sciences, AstraZeneca | Lung Cancer | 12/25 | 06/26 | | |
NCT04891900: TQB2450 Plus Anlotinib Combined With Chemotherapy in the Treatment of Gastric or Gastroesophageal Junction Adenocarcinoma |
|
|
| Active, not recruiting | N/A | 25 | RoW | TQB2450/Anlotinib hydrochloride/Oxaliplatin/Capecitabine, PD-L1 inhibitor/Anlotinib | Henan Cancer Hospital | Gastric Cancer, Adenocarcinoma of Esophagogastric Junction | 12/24 | 12/24 | | |
NCT05458778: Detection of Urinary Human Chorionic Gonadotropin (hCG) |
|
|
| Recruiting | N/A | 200 | US | Daily test with urine by the product | Quanovate Tech Inc. | Pregnancy Detection | 10/23 | 10/23 | | |
NCT05609058: The Influence of Treatment Position (Prone vs. Supine) on Whole Breast Target |
|
|
| Recruiting | N/A | 300 | RoW | dedicated treatment board with no degree | Cancer Institute and Hospital, Chinese Academy of Medical Sciences | Breast Cancer | 11/23 | 11/23 | | |
| Recruiting | N/A | 6 | RoW | QH104 Cell injection | Cancer Institute and Hospital, Chinese Academy of Medical Sciences | Solid Tumor, Meningeal Metastasis | 12/26 | 12/27 | | |
| Not yet recruiting | N/A | 74 | NA | Circum-psoas Block, Sham block | The Second Hospital of Shandong University | Acute Pain, Opioid Use | 04/25 | 05/25 | | |
NCT06509490: NKG2D CAR-T(KD-025) in the Treatment of Advanced NKG2DL+ Solid Tumors |
|
|
| Recruiting | N/A | 9 | RoW | KD-025 cell injection | Cancer Institute and Hospital, Chinese Academy of Medical Sciences | Safety Issues | 07/24 | 03/26 | | |
| Site, OBI Investigator |
NCT03562637: Study of Adagloxad Simolenin (OBI-822)/OBI-821 in the Adjuvant Treatment of Patients With Globo H Positive TNBC |
|
|
| Recruiting | 3 | 668 | Europe, US, RoW | adagloxad simolenin combined with OBI-821, Globo H IHC Assay, Standard of care treatment | OBI Pharma, Inc | Triple Negative Breast Cancer | 12/25 | 12/27 | | |
NCT03592264: A Phase I/II Study of OBI-3424 in Subjects with Advanced Solid Tumors |
|
|
| Terminated | 1/2 | 68 | US | OBI-3424 | OBI Pharma, Inc | Solid Tumor, Pancreatic Adenocarcinoma | 02/24 | 03/24 | | |
